# Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)

> **NCT05599789** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 47 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer Metastatic

## Interventions

- **DRUG:** Pembrolizumab in Combination with Plinabulin and Docetaxel

## Key facts

- **NCT ID:** NCT05599789
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-01
- **Primary completion:** 2025-01-21
- **Final completion:** 2025-12-31
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2025-02-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05599789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05599789, "Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05599789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*